Dr. James A. Davis, MD
Nephrology (Kidney) (Nephrology Physician)
10 Barnes West Dr, Div Im Nephrology, Ste 200
Saint Louis, MO 63141
Who else practices at this address →
St. Louis County includes dental (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Kentucky College of Medicine (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 387
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: University of Kentucky College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
MO license 2017033773
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Christ Hospital Cincinnati, OH
- St Elizabeth Edgewood Edgewood, KY
- St Elizabeth Florence Florence, KY
- St Elizabeth Ft Thomas Fort Thomas, KY
- St Elizabeth Grant Williamstown, KY
Medical groups
- Kidney and Hypertension Center Inc (48 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 387
- Services billed
- 1,478
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 453 | 165 |
| Established patient office or other outpatient visit, 30-39 minutes | 201 | 96 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 142 | 69 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 82 | 15 |
| Insertion of needle and/or tube into hemodialysis circuit and balloon dilation of dialysis segment with review by radiologist | 57 | 53 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 43 | 41 |
| New patient office or other outpatient visit, 45-59 minutes | 38 | 38 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 36 | 35 |
| Hemodialysis procedure with physician evaluation | 35 | 21 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 26 | 26 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Losartan Potassium Other prescribers in Saint Louis, MO | 106 |
| Furosemide Other prescribers in Saint Louis, MO | 79 |
| Amlodipine Besylate Other prescribers in Saint Louis, MO | 68 |
| Jardiance (empagliflozin) Other prescribers in Saint Louis, MO | 53 |
| Nifedipine Er (nifedipine) Other prescribers in Saint Louis, MO | 53 |
| Potassium Chloride Other prescribers in Saint Louis, MO | 50 |
| Carvedilol Other prescribers in Saint Louis, MO | 46 |
| Lisinopril Other prescribers in Saint Louis, MO | 43 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Saint Louis, MO | 42 |
| Metoprolol Succinate Other prescribers in Saint Louis, MO | 36 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 27 payments worth $477 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $81.02 |
|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $60.66 |
| Calliditas Therapeutics US Inc. | $50.70 |
| Bayer HealthCare Pharmaceuticals Inc. | $50.40 |
| Travere Therapeutics, Inc. | $49.82 |
| AstraZeneca Pharmaceuticals LP | $49.57 |
| Amgen Inc. | $42.41 |
| Novo Nordisk Inc | $19.33 |
| Food and Beverage | $471 |
|---|---|
| Education | $5.56 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Travere Therapeutics, Inc. Jun 11, 2025 | Education Thiola · Kidney Stones · in-kind | $3.01 |
| Travere Therapeutics, Inc. Jun 11, 2025 | Education Thiola · Kidney Stones · in-kind | $2.55 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $68,081 in research payments for these studies, mostly to the institutions running them.
- A phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outco…
AstraZeneca Pharmaceuticals LP - A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients…
Alnylam Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.